Trial · NCT02352831
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase I Only: Recommended Phase II Dose of Tosedostat | Phase I (Tosedostat + Capecitabine) | 120 | mg daily | ||
| Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLTs) | Phase I (Tosedostat + Capecitabine) | 1 | Participants | ||
| Progression-free Survival (PFS) Rate | Phase I (Tosedostat + Capecitabine) | 3 | Participants | ||
| Progression-free Survival (PFS) Rate | Phase II (Tosedostat + Capecitabine) | 8 | Participants | ||
| Progression-free Survival (PFS) Rate | Phase I and Phase II Combined | 11 | Participants | ||
| Overall Response Rate (ORR) | Phase I (Tosedostat + Capecitabine) | 0 | Participants | ||
| Overall Response Rate (ORR) | Phase II (Tosedostat + Capecitabine) | 0 | Participants | ||
| Time-to-progression (TTP) | Phase I (Tosedostat + Capecitabine) | 210.50 | Full Range 44.00 to 681.00 | days | |
| Time-to-progression (TTP) | Phase II (Tosedostat + Capecitabine) | 94.50 | Full Range 42.00 to 250.00 | days | |
| Overall Survival Rate (OS) | Phase I (Tosedostat + Capecitabine) | 3 | Participants | ||
| Overall Survival Rate (OS) | Phase II (Tosedostat + Capecitabine) | 2 | Participants | ||
| Overall Survival Rate (OS) | Phase I and Phase II (Tosedostat + Capecitabine) | 5 | Participants | ||
| Number of Participants With a CA19-9 Response | Phase I (Tosedostat + Capecitabine) | 6 | Participants | ||
| Number of Participants With a CA19-9 Response | Phase II (Tosedostat + Capecitabine) | 10 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02352831/results